ReviewStem cell reports2021
Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails.
Review in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Harnessing three-dimensional (3D) cell culture models for pulmonary infections: State of the art and future directions.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Induced Pluripotent Stem Cell-Derived Organoids: Their Implication in COVID-19 Modeling.International journal of molecular sciences · 2023Review
- COVID-19's immuno-pathology and cardiovascular diseases.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023Review
- Spike-based adenovirus vectored COVID-19 vaccine does not aggravate heart damage after ischemic injury in mice.Communications biology · 2022Article
- The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: Implications for COVID-19 vascular research.Stem cell reports · 2022Article
- Microphysiological stem cell models of the human heart.Materials today. Bio · 2022Review
- Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System.Stem cell reviews and reports · 2021Review
- Review
- Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2.Stem cell reports · 2021Article
- Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection.Communications biology · 2021Article
- Different kinds of stem cells in the development of SARS-CoV-2 treatments.World journal of stem cells · 2021Review
- 3D Cell Culture Models in COVID-19 Times: A Review of 3D Technologies to Understand and Accelerate Therapeutic Drug Discovery.Biomedicines · 2021Review
- ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis.International journal of molecular sciences · 2021Review
- COVID-19 and Cardiovascular Disease: From Bench to Bedside.Circulation research · 2021Review
- Recent Advances of COVID-19 Modeling Based on Regenerative Medicine.Frontiers in cell and developmental biology · 2021Review
- Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery.Frontiers in cell and developmental biology · 2021Review
- 2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases.Cardiology plusArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the coronavirus disease (COVID-19) outbreak that became a pandemic in 2020, causing more than 30 million infections and 1 million deaths to date. As the scientific community has looked for vaccines and drugs to treat or eliminate the virus, unexpected features of the disease have emerged. Apart from respiratory complications, cardiovascular disease has emerged as a major indicator of poor prognosis in COVID-19. It has therefore become of utmost importance to understand how SARS-CoV-2 damages the heart. Human pluripotent stem cell (hPSC) cardiovascular derivatives were rapidly recognized as an invaluable tool to address this, not least because one of the major receptors for the virus is not recognized by SARS-CoV-2 in mice. Here, we outline how hPSC-derived cardiovascular cells have been utilized to study COVID-19, and their potential for further understanding the cardiac pathology and in therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.